Tumor analysis in pTαko and CD3ϵko T-ALL models
| No. . | Genotype . | Time, months . | Phenotype . | CD3 CD8SP . |
|---|---|---|---|---|
| 4 | pTα−/−LMO1+/− | 7.8 | DP+CD8SP | Low |
| 15 | pTα−/−LMO1+/− | 8.8 | DP | Low |
| 21 | pTα−/−LMO1+/− | 8.8 | DN+DP+CD8SP | Low |
| 32 | pTα−/−LMO1+/− | 7.3 | CD8SP | Low |
| 174 | pTα−/−LMO1+/− | 8.5 | DN+DP+CD8SP | High |
| 223 | pTα−/−LMO1+/− | 9.8 | DN+DP+CD4SP | Low |
| 251 | pTα−/−LMO1+/− | 8.2 | DP | Low |
| 6 | pTα−/−TAL1+/−LMO1+/− | 7.8 | DN+DP+CD8SP | High |
| 16 | pTα−/−TAL1+/−LMO1+/− | 8.8 | DP | Low |
| 22 | pTα−/−TAL1+/−LMO1+/− | 8.2 | DP+CD8SP | High |
| 36 | pTα−/−TAL1+/−LMO1+/− | 6.7 | DP+CD8SP | Low+int |
| 43 | pTα−/−TAL1+/−LMO1+/− | 6.7 | CD8SP | High |
| 177 | pTα−/−TAL1+/−LMO1+/− | 5.7 | DP | Low+int |
| 176 | pTα−/−TAL1+/−LMO1+/− | 6.4 | DP+CD8SP | Low+int |
| 155 | pTα−/−TAL1+/−LMO1+/− | 5.4 | DN+CD8SP | Low |
| 183 | pTα−/−TAL1+/−LMO1+/− | 6.7 | DN+CD8SP | Low |
| 193 | pTα−/−TAL1+/−LMO1+/− | 6.3 | DN+CD8SP | Low+int |
| 213 | pTα−/−TAL1+/−LMO1+/− | 7.6 | DN+CD8SP | Low |
| 217 | pTα−/−TAL1+/−LMO1+/− | 5.2 | DN+DP+CD4SP+CD8SP | Low+int |
| 7 | CD3ϵ−/−LMO1+/− | 7.2 | DP | Neg |
| 7b | CD3ϵ−/−LMO1+/− | 7.4 | DP | Neg |
| 8 | CD3ϵ−/−LMO1+/− | 7.2 | ND | ND |
| 20 | CD3ϵ−/−LMO1+/− | 7.5 | DN | Neg |
| 38 | CD3ϵ−/−LMO1+/− | 6.4 | DN+DP | Neg |
| 40 | CD3ϵ−/−LMO1+/− | 9.6 | ND | ND |
| 44 | CD3ϵ−/−LMO1+/− | 4.8 | DP | Neg |
| 47 | CD3ϵ−/−LMO1+/− | 8.2 | ND | ND |
| 59 | CD3ϵ−/−LMO1+/− | 4.2 | DP | Neg |
| 60 | CD3ϵ−/−LMO1+/− | 7.8 | DP | Neg |
| 63 | CD3ϵ−/−LMO1+/− | 7.3 | DP+CD4SP | Neg |
| 66 | CD3ϵ−/−LMO1+/− | 8.9 | ND | ND |
| 73 | CD3ϵ−/−LMO1+/− | 8.6 | ND | ND |
| No. . | Genotype . | Time, months . | Phenotype . | CD3 CD8SP . |
|---|---|---|---|---|
| 4 | pTα−/−LMO1+/− | 7.8 | DP+CD8SP | Low |
| 15 | pTα−/−LMO1+/− | 8.8 | DP | Low |
| 21 | pTα−/−LMO1+/− | 8.8 | DN+DP+CD8SP | Low |
| 32 | pTα−/−LMO1+/− | 7.3 | CD8SP | Low |
| 174 | pTα−/−LMO1+/− | 8.5 | DN+DP+CD8SP | High |
| 223 | pTα−/−LMO1+/− | 9.8 | DN+DP+CD4SP | Low |
| 251 | pTα−/−LMO1+/− | 8.2 | DP | Low |
| 6 | pTα−/−TAL1+/−LMO1+/− | 7.8 | DN+DP+CD8SP | High |
| 16 | pTα−/−TAL1+/−LMO1+/− | 8.8 | DP | Low |
| 22 | pTα−/−TAL1+/−LMO1+/− | 8.2 | DP+CD8SP | High |
| 36 | pTα−/−TAL1+/−LMO1+/− | 6.7 | DP+CD8SP | Low+int |
| 43 | pTα−/−TAL1+/−LMO1+/− | 6.7 | CD8SP | High |
| 177 | pTα−/−TAL1+/−LMO1+/− | 5.7 | DP | Low+int |
| 176 | pTα−/−TAL1+/−LMO1+/− | 6.4 | DP+CD8SP | Low+int |
| 155 | pTα−/−TAL1+/−LMO1+/− | 5.4 | DN+CD8SP | Low |
| 183 | pTα−/−TAL1+/−LMO1+/− | 6.7 | DN+CD8SP | Low |
| 193 | pTα−/−TAL1+/−LMO1+/− | 6.3 | DN+CD8SP | Low+int |
| 213 | pTα−/−TAL1+/−LMO1+/− | 7.6 | DN+CD8SP | Low |
| 217 | pTα−/−TAL1+/−LMO1+/− | 5.2 | DN+DP+CD4SP+CD8SP | Low+int |
| 7 | CD3ϵ−/−LMO1+/− | 7.2 | DP | Neg |
| 7b | CD3ϵ−/−LMO1+/− | 7.4 | DP | Neg |
| 8 | CD3ϵ−/−LMO1+/− | 7.2 | ND | ND |
| 20 | CD3ϵ−/−LMO1+/− | 7.5 | DN | Neg |
| 38 | CD3ϵ−/−LMO1+/− | 6.4 | DN+DP | Neg |
| 40 | CD3ϵ−/−LMO1+/− | 9.6 | ND | ND |
| 44 | CD3ϵ−/−LMO1+/− | 4.8 | DP | Neg |
| 47 | CD3ϵ−/−LMO1+/− | 8.2 | ND | ND |
| 59 | CD3ϵ−/−LMO1+/− | 4.2 | DP | Neg |
| 60 | CD3ϵ−/−LMO1+/− | 7.8 | DP | Neg |
| 63 | CD3ϵ−/−LMO1+/− | 7.3 | DP+CD4SP | Neg |
| 66 | CD3ϵ−/−LMO1+/− | 8.9 | ND | ND |
| 73 | CD3ϵ−/−LMO1+/− | 8.6 | ND | ND |
The tumor data for all numbers are positive.
SP indicates single-positive CD4+ or CD8+; DP, double-positive CD4+CD8+; DN, double-negative CD4−CD8−; Int, intermediate; Neg, native; and ND, not determined.
Numbers correspond to nucleotide position in cDNA.